The ADC market offers significant growth opportunities driven by the rising cancer incidence and demand for targeted therapies, which improve efficacy and reduce toxicity. Advancements in precision ...

Key market opportunities in next-generation drug conjugates are driven by their precision in targeting rare diseases and cancers, owing to their enhanced clinical profiles and varied targeting agents ...

The global cancer antibody drug conjugates market is experiencing significant expansion, with a projected increase from $8.19 billion in 2024 to $9.17 billion in 2025, reflecting ...

You may have heard of the consulting firm Gartner’s technology hype cycle—the technology trigger, the peak of inflated expectations, the trough of disillusionment, the slope of enlightenment, and the ...

From hair regrowth to safe pregnancy chemotherapy and new targeted therapies, these top five breast cancer stories of 2025 ...

Chemotherapy is one of the most widely used cancer therapies; however, chemotherapy often causes serious side effects. Antibody-drug conjugates (ADCs) are promisingly emerging cancer therapies that ...

† PEG-Naloxol (NKTR-118) in Phase II clinical trials. Clinical benefit has already been demonstrated with polymer–drug conjugates bearing classical chemotherapeutic agents. The future of cancer ...

Although just two ADCs, Seattle Genetics’ Adcetris and Roche’s Kadcyla, are on the market, they are proof that the products are technically feasible, therapeutically effective, and able to get ...

Vantage Market Research report examines the Antibody Drug Conjugates (ADCs) market, forecasting trends and dynamics from 2025 to 2035. The report highlights the significance of ADCs in modern oncology ...